South San Francisco-based biotechnology company Exelixis Inc. (EXEL) said it has netted approximately $71.8 million through its public offering of 7 million shares of common stock.
Underwriter Goldman, Sachs & Co. has also been granted a 30-day option to purchase up to an additional 1.05 million shares of common stock.
Upgraded culinary center could serve as model for expanded in-house food production.
A simple engineering change could soon make Muni’s 900 buses roomier across… Continue reading
Mayor London Breed has given City Hall a deadline to close down… Continue reading
San Francisco-based e-scooter company Skip this week announced pending layoffs for roughly… Continue reading
San Francisco-based e-cigarette maker Juul Labs announced Thursday that it is suspending… Continue reading
